Cite
Hodge RJ, Lin J, Vasist Johnson LS, et al. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013;2(3):213-22doi: 10.1002/cpdd.34.
Hodge, R. J., Lin, J., Vasist Johnson, L. S., Gould, E. P., Bowers, G. D., Nunez, D. J. (2013). Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clinical pharmacology in drug development, 2(3), 213-22. https://doi.org/10.1002/cpdd.34
Hodge, Rebecca J, et al. "Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes." Clinical pharmacology in drug development vol. 2,3 (2013): 213-22. doi: https://doi.org/10.1002/cpdd.34
Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22. doi: 10.1002/cpdd.34. Epub 2013 May 14. PMID: 27121782.
Copy
Download .nbib